OSE Immuno: up on analysts' comments
OSE Immuno has had an explosive start to 2024 (+134% since the end of February), supported by major announcements on the business development front", notes the analyst, citing the licensing agreement with Abbvie and the amendment to the collaboration with BI.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction